Gracell Bio (GRCL) Stock Forecast, Price Target & Predictions
GRCL Stock Forecast
Gracell Bio stock forecast is as follows: an average price target of $6.00 (represents a -41.46% downside from GRCL’s last price of $10.25) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
GRCL Price Target
GRCL Analyst Ratings
Gracell Bio Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Dec 08, 2022 | - | H.C. Wainwright | $6.00 | $2.63 | 128.14% | -41.46% |
Gracell Bio Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | - |
Avg Price Target | - | - | - |
Last Closing Price | $10.25 | $10.25 | $10.25 |
Upside/Downside | -100.00% | -100.00% | -100.00% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Sep 22, 2022 | Citigroup | - | Negative | Initialise |
Jun 01, 2022 | Cantor Fitzgerald | - | Overweight | Initialise |
Apr 04, 2022 | BTIG | - | Buy | Initialise |
Gracell Bio Financial Forecast
Gracell Bio Revenue Forecast
Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | $366.00K |
Avg Forecast | - | - | - | - | - | - | $125.00K | $366.00K | $366.00K |
High Forecast | - | - | - | - | - | - | $88.83K | $260.09K | $439.20K |
Low Forecast | - | - | - | - | - | - | $146.28K | $428.30K | $292.80K |
# Analysts | 10 | 10 | 10 | 10 | 10 | 18 | 10 | 10 | 20 |
Surprise % | - | - | - | - | - | - | - | - | 1.00% |
Gracell Bio EBITDA Forecast
Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|---|---|---|---|
# Analysts | 10 | 10 | 10 | 10 | 10 | 18 | 10 | 10 | 20 |
EBITDA | - | - | - | - | - | - | $-151.34M | $-127.26M | $-128.20M |
Avg Forecast | - | - | - | - | - | - | $75.00K | $219.60K | $-128.20M |
High Forecast | - | - | - | - | - | - | $53.30K | $156.06K | $-102.56M |
Low Forecast | - | - | - | - | - | - | $87.77K | $256.98K | $-153.84M |
Surprise % | - | - | - | - | - | - | -2017.83% | -579.50% | 1.00% |
Gracell Bio Net Income Forecast
Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|---|---|---|---|
# Analysts | 10 | 10 | 10 | 10 | 10 | 18 | 10 | 10 | 20 |
Net Income | - | - | - | - | - | - | $-151.73M | $-116.26M | $-129.28M |
Avg Forecast | $105.23M | $91.66M | $107.62M | $-18.43M | $-19.12M | $-25.26M | $-23.89M | $8.19M | $-129.28M |
High Forecast | $67.17M | $58.51M | $68.70M | $-17.07M | $-13.65M | $-16.12M | $-15.25M | $5.23M | $-103.43M |
Low Forecast | $127.62M | $111.16M | $130.52M | $-20.48M | $-20.48M | $-30.63M | $-28.98M | $9.94M | $-155.14M |
Surprise % | - | - | - | - | - | - | 6.35% | -14.19% | 1.00% |
Gracell Bio SG&A Forecast
Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|---|---|---|---|
# Analysts | 10 | 10 | 10 | 10 | 10 | 18 | 10 | 10 | 20 |
SG&A | - | - | - | - | - | - | $29.09M | $32.00M | $42.86M |
Avg Forecast | - | - | - | - | - | - | - | - | $42.86M |
High Forecast | - | - | - | - | - | - | - | - | $51.43M |
Low Forecast | - | - | - | - | - | - | - | - | $34.29M |
Surprise % | - | - | - | - | - | - | - | - | 1.00% |
Gracell Bio EPS Forecast
Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|---|---|---|---|
# Analysts | 10 | 10 | 10 | 10 | 10 | 18 | 10 | 10 | 20 |
EPS | - | - | - | - | - | - | $-2.24 | $-1.77 | $-1.90 |
Avg Forecast | $1.54 | $1.34 | $1.58 | $-0.27 | $-0.28 | $-0.37 | $-0.35 | $0.12 | $-0.05 |
High Forecast | $0.98 | $0.86 | $1.01 | $-0.25 | $-0.20 | $-0.24 | $-0.22 | $0.08 | $-0.03 |
Low Forecast | $1.87 | $1.63 | $1.91 | $-0.30 | $-0.30 | $-0.45 | $-0.42 | $0.15 | $-0.06 |
Surprise % | - | - | - | - | - | - | 6.40% | -14.75% | 38.00% |
Gracell Bio Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
CHRS | Coherus BioSciences | $0.72 | $9.00 | 1150.00% | Hold |
SPRO | Spero Therapeutics | $1.18 | $10.00 | 747.46% | Buy |
XFOR | X4 Pharmaceuticals | $0.52 | $3.67 | 605.77% | Buy |
CTMX | CytomX Therapeutics | $1.05 | $5.77 | 449.52% | Buy |
INZY | Inozyme Pharma | $4.36 | $14.67 | 236.47% | Buy |
DAWN | Day One Biopharmaceuticals | $14.65 | $38.80 | 164.85% | Buy |
ERAS | Erasca | $2.72 | $7.00 | 157.35% | Buy |
ABOS | Acumen Pharmaceuticals | $2.85 | $7.00 | 145.61% | Buy |
NXTC | NextCure | $1.33 | $3.00 | 125.56% | Buy |
ASMB | Assembly Biosciences | $16.89 | $35.50 | 110.18% | Buy |
TERN | Terns Pharmaceuticals | $6.94 | $14.25 | 105.33% | Buy |
DSGN | Design Therapeutics | $5.20 | $9.67 | 85.96% | Buy |
BOLT | Bolt Biotherapeutics | $0.66 | $1.00 | 51.52% | Hold |
BPMC | Blueprint Medicines | $90.70 | $109.71 | 20.96% | Buy |
AMLX | Amylyx Pharmaceuticals | $5.64 | $5.33 | -5.50% | Buy |
GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |
GRCL Forecast FAQ
Is Gracell Bio a good buy?
Yes, according to 3 Wall Street analysts, Gracell Bio (GRCL) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of GRCL's total ratings.
What is GRCL's price target?
Gracell Bio (GRCL) average price target is $6 with a range of $6 to $6, implying a -41.46% from its last price of $10.25. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Gracell Bio stock go up soon?
According to Wall Street analysts' prediction for GRCL stock, the company can go down by -41.46% (from the last price of $10.25 to the average price target of $6), down by -41.46% based on the highest stock price target, and down by -41.46% based on the lowest stock price target.
Can Gracell Bio stock reach $20?
GRCL's average twelve months analyst stock price target of $6 does not support the claim that Gracell Bio can reach $20 in the near future.
What are Gracell Bio's analysts' financial forecasts?
GRCL's analysts financial forecasts for the fiscal year (Dec 2023) are as follows: average revenue is $125K (high $88.83K, low $146.28K), average EBITDA is $75K (high $53.3K, low $87.76K), average net income is $-86.703M (high $-62.097M, low $-101M), average SG&A $0 (high $0, low $0), and average EPS is $-1.27 (high $-0.91, low $-1.473).
Did the GRCL's actual financial results beat the analysts' financial forecasts?
Based on Gracell Bio's last annual report (Dec 2021), the company's revenue was $366K, which missed the average analysts forecast of $732K by -50.00%. Apple's EBITDA was $-385M, beating the average prediction of $-128M by 200.94%. The company's net income was $-453M, beating the average estimation of $-121M by 274.14%. Apple's SG&A was $137.04M, beating the average forecast of $42.86M by 219.73%. Lastly, the company's EPS was $-6.89, missing the average prediction of $0.07 by -9942.86%. In terms of the last quarterly report (Sep 2021), Gracell Bio's revenue was $366K, beating the average analysts' forecast of $366K by 0%. The company's EBITDA was $-128M, beating the average prediction of $-128M by 0%. Gracell Bio's net income was $-129M, beating the average estimation of $-129M by 0%. The company's SG&A was $42.86M, beating the average forecast of $42.86M by 0%. Lastly, the company's EPS was $-1.9, beating the average prediction of $-0.05 by 3700.00%